| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6632842 | MYLAN SPECIALITY LP | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
Dec, 2021
(2 years ago) | |
Duoneb is owned by Mylan Speciality Lp.
Duoneb contains Albuterol Sulfate; Ipratropium Bromide.
Duoneb has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Duoneb are:
- US6632842
Duoneb was authorised for market use on 21 March, 2001.
Duoneb is available in solution;inhalation dosage forms.
Duoneb can be used as treatment of bronchospasm associated with copd in patients requiring more than one broncho dilator.
The generics of Duoneb are possible to be released after 28 December, 2021.
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 21 March, 2001
Treatment: Treatment of bronchospasm associated with copd in patients requiring more than one broncho dilator
Dosage: SOLUTION;INHALATION
DUONEB family patents
